Taigen Biopharmaceuticals Holdings Ltd (4157) — Free Cash Flow Generation Index
Taigen Biopharmaceuticals Holdings Ltd (4157) has a Free Cash Flow Generation Index of 0.95x as of December 2025. Free cash flow of NT$44.27 Million represents 1% of operating cash flow (NT$46.51 Million). Read Taigen Biopharmaceuticals Holdings Ltd total liabilities for a breakdown of total debt and financial obligations.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
Taigen Biopharmaceuticals Holdings Ltd Free Cash Flow Generation Index (2021–2025)
Historical FCF Generation Index trend for Taigen Biopharmaceuticals Holdings Ltd across 3 annual periods. Explore Taigen Biopharmaceuticals Holdings Ltd capex to cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
Annual Free Cash Flow Generation for Taigen Biopharmaceuticals Holdings Ltd (2021–2025)
Year-by-year Free Cash Flow Generation Index for Taigen Biopharmaceuticals Holdings Ltd. For the full company profile including market capitalisation, see Taigen Biopharmaceuticals Holdings Ltd market capitalisation.
| Year | FCG Index | Free Cash Flow (TWD) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.78x | NT$16.42 Million | NT$20.93 Million | NT$4.50 Million | ▲ +21.9% |
| 2023 | 0.64x | NT$13.35 Million | NT$20.74 Million | NT$7.39 Million | ▼ -34.4% |
| 2021 | 0.98x | NT$617.24 Million | NT$629.07 Million | NT$11.83 Million | — |